Improving radiation therapy for prostate cancer using targeted molecules
PSMA ligand radiosensitizers to improve the therapeutic index of external beam radiotherapy for prostate cancer
This study is looking at new ways to make radiation therapy for prostate cancer work better by using special molecules that target cancer cells, which could help improve treatment results and reduce side effects for patients.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11057708 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of radiation therapy for prostate cancer by developing specialized molecules that target prostate-specific antigens. The approach involves creating two new compounds that link a PSMA ligand to radiation-sensitizing agents, which may improve the treatment's efficacy while minimizing damage to surrounding healthy tissues. The research will include laboratory tests on prostate cancer cell lines and animal models to evaluate how well these new compounds work and their potential side effects. Patients may benefit from improved treatment options that could lead to better outcomes and fewer complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with high-risk or metastatic prostate cancer who are undergoing radiation therapy.
Not a fit: Patients with non-prostate cancers or those who are not receiving radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective radiation treatments for prostate cancer with reduced side effects.
How similar studies have performed: Other research has shown promising results using targeted therapies in cancer treatment, suggesting potential for success with this novel approach.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Higginson, Daniel — Sloan-Kettering Inst Can Research
- Study coordinator: Higginson, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.